Gupta N C, Esterbrooks D J, Hilleman D E, Mohiuddin S M
Division of Nuclear Medicine, Creighton University School of Medicine, Omaha, Nebraska 68131.
J Am Coll Cardiol. 1992 Feb;19(2):248-57. doi: 10.1016/0735-1097(92)90474-2.
Pharmacologic stress with dipyridamole has provided useful diagnostic, as well as prognostic, information in patients undergoing thallium-201 myocardial perfusion imaging. With its ultrashort half-life and a potent and consistent vasodilator effect, adenosine may be the coronary vasodilator of choice with myocardial perfusion imaging. Fifty-one healthy subjects and 93 patients with suspected coronary artery disease constituted the study group. In this multicenter study the comparative safety and diagnostic efficacy of single-photon emission computed tomography (SPECT) thallium imaging during adenosine-induced coronary hyperemia was compared with exercise treadmill stress. There was a mean increase in heart rate of 37% and a mean decrease in diastolic blood pressure of 5% during the adenosine infusion of 140 micrograms/kg per min for 6 min. Adenosine infusion was well tolerated in 95% of the subjects. Side effects requiring intervention occurred in seven subjects (5%). None of the subjects experienced a life-threatening complication. The sensitivity, specificity and predictive accuracy for detection of coronary artery disease with use of quantitative analysis was 83%, 87% and 84% for adenosine SPECT and 82%, 80% and 81% for exercise SPECT studies, respectively. Most false negative results with adenosine, as well as exercise SPECT studies, occurred in patients with single-vessel disease. The first-order concordance (no defect vs. defect) and second-order concordance (no defect vs. irreversible vs. reversible defect) was 89% and 78% between the two studies, respectively. Thus, the results of adenosine SPECT imaging are highly concordant with exercise SPECT thallium imaging. Adenosine SPECT thallium imaging provides a safe and highly accurate imaging mode for the detection of coronary artery disease.
双嘧达莫药物负荷试验已为接受铊 - 201心肌灌注显像的患者提供了有用的诊断及预后信息。腺苷具有超短半衰期以及强效且持续的血管扩张作用,它可能是心肌灌注显像时冠状动脉扩张剂的首选。51名健康受试者和93名疑似冠心病患者构成了研究组。在这项多中心研究中,比较了腺苷诱导冠状动脉充血期间单光子发射计算机断层扫描(SPECT)铊显像与运动平板负荷试验的相对安全性和诊断效能。在以每分钟140微克/千克的速度输注腺苷6分钟期间,心率平均增加37%,舒张压平均降低5%。95%的受试者对腺苷输注耐受性良好。7名受试者(5%)出现需要干预的副作用。没有受试者发生危及生命的并发症。使用定量分析检测冠心病时,腺苷SPECT的敏感性、特异性和预测准确性分别为83%、87%和84%,运动SPECT研究分别为82%、80%和81%。腺苷以及运动SPECT研究的大多数假阴性结果发生在单支血管病变的患者中。两项研究之间的一级一致性(无缺损与有缺损)和二级一致性(无缺损与不可逆缺损与可逆缺损)分别为89%和78%。因此,腺苷SPECT显像结果与运动SPECT铊显像高度一致。腺苷SPECT铊显像为检测冠心病提供了一种安全且高度准确的显像模式。